2-(2-((4-(Piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)benzofuran-5-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(2-((4-(Piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)benzofuran-5-carbonitrile
• 英文别名: 2-[2-(4-Piperazin-1-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]-1-benzofuran-5-carbonitrile；2-[2-(4-piperazin-1-ylanilino)-5-(trifluoromethyl)pyrimidin-4-yl]-1-benzofuran-5-carbonitrile
• 化学式: C₂₄H₁₉F₃N₆O
• 分子量: 464.45
• InChiKey: HCFNKSWBMGNACO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  90
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-Boc-4-(4-氨基苯基)哌嗪 在 四(三苯基膦)钯 、 sodium carbonate 、 三乙胺 、 三氟乙酸 、 zinc(II) chloride 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 6.5h， 生成 2-(2-((4-(Piperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)benzofuran-5-carbonitrile
  参考文献：
  名称：

  Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors

  摘要：

  Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[ 3,2-c] pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.10.011

文献信息

• Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors
  作者：Yazhou Wang、Wei Huang、Minhang Xin、Pan Chen、Li Gui、Xinge Zhao、Feng Tang、Jia Wang、Fei Liu

  DOI：10.1016/j.bmc.2016.10.011

  日期：2017.1

  Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[ 3,2-c] pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib. (C) 2016 Elsevier Ltd. All rights reserved.